Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
NCT04717245 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75
Last updated 2021-01-25
Summary
Postmenopausal hypoestrogenism may determine genital atrophy, which may be accompanied by a non-specific inflammatory process and may hinder or even prevent sexual intercourse. In more severe cases, the patient may have local pain that interferes with their daily activities. The best treatment for increasing genital trophism is still estrogen. However, there are women who can not use this therapy or do not want it. Therefore, there is a need for alternatives, such as ablation techniques: use of CO2 LASER and fractional radiofrequency.
The study was carried out at the outpatient clinic of Lower Genital Tract ambulatory of the Discipline of Gynecology, Department of Obstetrics and Gynecology, Clinical Hospital, Faculty of Medicine, University of São Paulo, involving 75 women who were divided after randomization in three groups:
Group 1 - treatment with topical vaginal promestriene (n = 25 patients); Group 2 - treatment with fractional CO2 LASER (n = 25 patients); Group 3 - fractional microablative radiofrequency treatment (n = 25 patients).
An evaluation of the complaints were be performed through questionnaires on sexuality, quality of life and urinary incontinence, as well as biopsies of the vaginal wall for histomorphometric, immunohistochemical and molecular biology study before and after six months of treatment. The duration of the study were fifteen months.
Conditions
- Vaginal Atrophy
Interventions
- DRUG
-
Promestriene Vaginal
Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
- OTHER
-
Fractional CO2 LASER
LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination. Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1
- OTHER
-
Microablative Fractional radiofrequency
Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure. The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution. All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third.
Sponsors & Collaborators
-
University of Sao Paulo General Hospital
lead OTHER
Principal Investigators
-
Jose Maria Soares Junior, PHD · Universidade de São Paulo departamento de ginecologia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-25
- Primary Completion
- 2019-03-07
- Completion
- 2020-02-18
Countries
- Brazil
Study Locations
More Related Trials
-
Vulvovaginal Atrophy Correction Using Neodymium Laser
NCT04735549 ·Status: COMPLETED ·Phase: NA
-
Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women.
NCT04487392 ·Status: WITHDRAWN ·Phase: PHASE2
-
Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
NCT02691936 ·Status: COMPLETED ·Phase: NA
-
Effect of Hybrid Laser 10600+1540 nm on GSM
NCT03956563 ·Status: UNKNOWN ·Phase: NA
-
Randomized, Controlled Trial With Hybrid Fractional Laser
NCT03647189 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy
NCT06514586 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis
NCT05118685 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.
NCT04574999 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors
NCT05713435 ·Status: RECRUITING ·Phase: NA
-
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
NCT03740945 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM)
NCT07034976 ·Status: RECRUITING ·Phase: NA
-
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
NCT04232813 ·Status: COMPLETED ·Phase: PHASE3
-
Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
NCT03032848 ·Status: COMPLETED ·Phase: PHASE4
-
Genital Laser Treatment in Postmenopausal Patients
NCT05631665 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy
NCT05151380 ·Status: COMPLETED ·Phase: NA
-
Vaginal Estrogen Treatment and Effect on Hemostatic Parameters in Postmenopausal Women
NCT07160504 ·Status: RECRUITING ·Phase: PHASE4
-
Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
NCT02967510 ·Status: COMPLETED ·Phase: PHASE2
-
Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
NCT02460302 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
NCT00276094 ·Status: COMPLETED ·Phase: PHASE3
-
Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
NCT01122342 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)
NCT06318052 ·Status: RECRUITING ·Phase: NA
-
Clinical Study to Evaluate the Efficacy of Prasterone Treatment for Atrophy Vulvovaginal in Postmenopausal Women With Vulvar / Vestibular Pain
NCT04898556 ·Status: UNKNOWN ·Phase: PHASE3
-
Laser Vaginal Treatment for GSM
NCT04042766 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Clinical Study to Evaluate the Safety of Ospemifene
NCT00566982 ·Status: COMPLETED ·Phase: PHASE3
-
Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause
NCT02013544 ·Status: COMPLETED ·Phase: PHASE3